Brazil Approves 5 New Semaglutide Brands, Price Drops Expected, SUS Inclusion Eyed
Brazil's National Health Surveillance Agency (Anvisa) has approved five new brands of semaglutide-based weight-loss pens, five months after the drug's patent expired in the country. The newly approved medications include Zempneo (Brainfarma), Semavy (Cosmed), Orsema (Ranbaxy), Seemasun (Sun Farmacêutica), and Owozy (Ávita Care). While Anvisa's approval expands the availability of GLP-1 medications, the final consumer price is yet to be determined by the Chamber of Regulation of the Drug Market (CMED), an Anvisa-linked body that sets maximum sale prices. The Ministry of Health has requested expedited review of these prices, with a decision anticipated within weeks, possibly by early August, mirroring the timeline of the first national semaglutide release by EMS. The Brazilian market demonstrates significant demand for these drugs, with GLP-1s generating R$11.45 billion in 2025 and R$5.54 billion in the first four months of 2026. Increased competition is expected to drive down prices and potentially facilitate the inclusion of semaglutide in the public health system (SUS). Previously, a semaglutide pen cost around R$1,000 per month, but prices have fallen to just over R$300 following the patent expiry and increased competition. Experts anticipate further price reductions with the introduction of these five new brands. The potential inclusion in SUS, which was previously stalled due to high costs (estimated at R$4.1 billion over five years), is being re-evaluated by the National Commission for the Incorporation of Technologies in SUS (Conitec) in September. Novo Nordisk has submitted a new proposal with significant discounts, offering doses ranging from R$396.88 to R$764.64. A pilot program with semaglutide is also underway at the Grupo Hospitalar Conceição in Porto Alegre to gather data for potential public system protocols. Doctors emphasize that access to such treatments within the SUS is crucial, especially given that obesity affects a quarter of the Brazilian population and is more prevalent among lower-income individuals, who rely heavily on public healthcare. Currently, bariatric surgery is the primary treatment option for obesity within the SUS, with over 6 million people on the waiting list.
The Brazilian regulatory approval of multiple semaglutide brands signifies a pivotal market shift, driven by patent expirations and a strategic response to high demand and pricing. This increased competition is a natural market dynamic that should lead to more accessible pricing, a critical factor for potential inclusion in the public health system (SUS). The government's proactive engagement in expediting price regulation and initiating pilot programs suggests a systemic effort to address the significant public health burden of obesity. The challenge for policymakers lies in balancing the cost-effectiveness of new treatments with the long-term healthcare savings derived from managing obesity-related comorbidities. Future evaluations by Conitec will likely weigh these economic factors against the demonstrable clinical benefits and the societal imperative for equitable access to advanced medical therapies, particularly as the global pharmaceutical landscape increasingly focuses on metabolic health solutions.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.